Promising activity against NTERA-2 cancer stem cells of malloapelta B compound isolated from the Bum-bup plant in Vietnam
Author affiliations
DOI:
https://doi.org/10.15625/1811-4989/18/1/15270Keywords:
CD44, CD24, cancer stem cells CSCs, malloapelta B, NTERA-2Abstract
Recent studies have revealed that cancer stem cells (CSCs) drive tumor growth, metastasis, therapy resistant and recurrence. Therefore, CSCs are considered as new targets for screening of more effective drugs. The compound malloapelta B, which was isolated from the Bum-bup plant (Mallotus apelta) (Lour.) Muel.-Arg, Euphorbiaceae) in Vietnam, presented very potent and strong anticancer invitro, especially against the activation ofNF-kB (nuclear factor- kappa B). In our research, malloapelta B inhibited the growth of NTERA-2 line, a CSC line, at the value of IC50 = 12.71 ± 0.76 µM. In this study, malloapelta B also had effects on cell cycle of NTERA-2 by significantly reducing the cell number at G0/G1 phase (37.48%), while raising this number of phase G2/M to 31.12% in comparison with those of control (56.81% and 18.6%, respectively). Besides, clonogenic and tumorspheroidal formations are acknowledged as typically renewable characteristics of CSCs. Then, in our studies, malloapelta B significantly prevented NTERA-2 to form clonogens and reduced tumorspheres’ sizes at treatments with 20 and 100 µg/mL. However, malloapelta B did not exhibit any obvious effects on the expression level of CD44+/CD24+, the two typical cell surface markers of CSCs, at 2.5 and 5 µM treatments.Downloads
Downloads
Published
How to Cite
Issue
Section
License
Vietnam Journal of Biotechnology is a peer-reviewed, open access journal dedicated to the dissemination of scientific knowledge and research findings in the field of biotechnology. All published articles are freely accessible and downloadable by readers worldwide without any subscription or access fees.
All articles published in Vietnam Journal of Biotechnology are distributed under the terms of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) License. This license allows users to share, copy, redistribute, adapt, and reproduce the material in any medium or format, provided that appropriate credit is given to the original author(s) and source, and that any derivative works are distributed under the same license terms.
The copyright of each published article remains with the respective author(s) without restriction. By submitting and granting permission for publication through the journal’s submission system or other communication channels, authors authorize Vietnam Journal of Biotechnology to publish and identify itself as the original publisher of the work. Authors also acknowledge and agree to comply with the terms and conditions of the CC BY-SA 4.0 License and the policies established by the journal.
